Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

阿帕蒂尼 医学 中性粒细胞减少症 耐受性 内科学 白细胞减少症 临床研究阶段 胃肠病学 贫血 转移性乳腺癌 乳腺癌 三阴性乳腺癌 不利影响 肿瘤科 癌症 毒性
作者
Xichun Hu,Jian Zhang,Binghe Xu,Zefei Jiang,Joseph Ragaz,Zhongsheng Tong,Qingyuan Zhang,Xiaojia Wang,Jifeng Feng,Danmei Pang,Minhao Fan,Jin Li,Biyun Wang,Zhonghua Wang,Qunling Zhang,Si Sun,Liao Chunmei
出处
期刊:International Journal of Cancer [Wiley]
卷期号:135 (8): 1961-1969 被引量:222
标识
DOI:10.1002/ijc.28829
摘要

Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer (mTNBC) in China. Phase IIa was first performed among 25 patients previously treated with anthracycline and/or taxane. All patients received apatinib 750 mg/day p.o. in a 4-week cycle. Subsequently, a phase IIb study of 59 patients was activated, with the endpoint progression-free survival (PFS). The dosage of drug for the Phase IIb was determined according to safety, tolerability and efficacy from the phase IIa study. As a result of toxicity associated with the 750 mg dose in phase IIa, the recommended initial dose of apatinib in the phase IIb was 500 mg/day. In phase IIb, grade 3/4 hematologic toxicities were thrombocytopenia (13.6%), leukopenia (6.8%), neutropenia (3.4%) and anemia (1.7%). The most frequent grade 3/4 nonhematologic toxicities were hand–foot syndrome, proteinuria, hypertension, and increased ALT. In the 56 evaluable patients, overall response rate and clinical benefit rate (CBR) were 10.7 and 25.0%, respectively. Median PFS and overall survival were 3.3 (95% CI 1.7–5.0) and 10.6 (95% CI 5.6–15.7) months, respectively. Our results indicate that apatinib dose of 500 mg rather than 750 mg is the recommended starting dose for the heavily pretreated mTNBC patients with measurable rate of partial response and PFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
rain6发布了新的文献求助10
刚刚
1秒前
1秒前
戏言121发布了新的文献求助10
1秒前
2秒前
2秒前
lc发布了新的文献求助10
4秒前
动人的笑白完成签到,获得积分20
4秒前
茶匙发布了新的文献求助10
4秒前
柳橙完成签到 ,获得积分10
5秒前
大意的羊完成签到,获得积分10
5秒前
科研通AI2S应助kjding采纳,获得10
6秒前
7秒前
研友_VZG7GZ应助lily采纳,获得10
7秒前
www发布了新的文献求助10
7秒前
jingjing发布了新的文献求助10
7秒前
冬叶完成签到,获得积分10
8秒前
8秒前
优秀的映萱完成签到,获得积分10
10秒前
邱小七发布了新的文献求助10
11秒前
11秒前
Sherwin发布了新的文献求助10
13秒前
yl完成签到,获得积分10
14秒前
15秒前
jingjing完成签到,获得积分20
16秒前
16秒前
hyx发布了新的文献求助10
17秒前
积极慕梅应助椰树椰汁采纳,获得10
17秒前
寒烟完成签到 ,获得积分10
18秒前
思源应助syf采纳,获得10
18秒前
小飞机完成签到,获得积分10
20秒前
geyunjie发布了新的文献求助10
21秒前
温婉的伟帮完成签到,获得积分10
21秒前
丘比特应助小鱼儿采纳,获得10
21秒前
JamesPei应助风色四叶草采纳,获得10
21秒前
汤圆圆儿完成签到,获得积分10
22秒前
Leslie发布了新的文献求助10
22秒前
Grace完成签到 ,获得积分10
22秒前
思源应助柳橙采纳,获得10
23秒前
lu完成签到,获得积分10
24秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
The Data Economy: Tools and Applications 1000
Diamonds: Properties, Synthesis and Applications 800
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufen 700
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3097793
求助须知:如何正确求助?哪些是违规求助? 2749704
关于积分的说明 7605682
捐赠科研通 2401576
什么是DOI,文献DOI怎么找? 1274203
科研通“疑难数据库(出版商)”最低求助积分说明 616015
版权声明 599016